M&A

J&J Becomes the Newest Player in the LAA Market
J&J Becomes the Newest Player in the LAA Market
Medical Devices and Diagnostics Industry
JNJ
M&A
Medtech
Penditure LAA
Flag link:
AbbVie pays $10B to acquire ImmunoGen, doubling down on red-hot ADC cancer field
AbbVie pays $10B to acquire ImmunoGen, doubling down on red-hot ADC cancer field
Fierce Pharma
AbbVie
M&A
antibody-drug conjugate
Immunogen
Elahere
ovarian cancer
Flag link:
Cigna, Humana in talks to merge
Cigna, Humana in talks to merge
BioPharma Dive
insurers
M&A
Cigna
Humana
Flag link:
Merck Drops Up to $610M on Neuro Disease-Focused Caraway Therapeutics
Merck Drops Up to $610M on Neuro Disease-Focused Caraway Therapeutics
BioSpace
Merck
M&A
neurodegenerative disease
Caraway Therapeutics
Flag link:
Astellas pays $175M for Propella, clearing early-phase rival to J&J's Zytiga for takeoff
Astellas pays $175M for Propella, clearing early-phase rival to J&J's Zytiga for takeoff
Fierce Biotech
Astellas
Propella Therapeutics
M&A
JNJ
Zytiga
prostate cancer
Flag link:
LENZ Therapeutics and Graphite Bio agree to merge
LENZ Therapeutics and Graphite Bio agree to merge
Pharmaceutical Technology
Graphite Bio
Lenz Therapeutics
M&A
presbyopia
Flag link:
Pencils down for Graphite, as gene editing biotech merges into vision-loss-focused Lenz
Pencils down for Graphite, as gene editing biotech merges into vision-loss-focused Lenz
Fierce Biotech
Lenz Therapeutics
Graphite Bio
gene editing
reverse merger
vision loss
M&A
Flag link:
Catalent delays quarterly filing with SEC on $700 mln impairment charge
Catalent delays quarterly filing with SEC on $700 mln impairment charge
Reuters
Catalent
SEC
M&A
Flag link:
Biogen's M&A, Alzheimer's drug launch costs spark profit forecast cut
Biogen's M&A, Alzheimer's drug launch costs spark profit forecast cut
Reuters
Biogen
Alzheimer's disease
Leqembi
Reata
M&A
earnings
Flag link:
Roivant’s $7B Roche deal was a ‘moment of opportunity,’ CEO says
Roivant’s $7B Roche deal was a ‘moment of opportunity,’ CEO says
BioPharma Dive
Roivant
Televant
M&A
Roche
Flag link:
United Therapeutics to Acquire Miromatrix Medical
United Therapeutics to Acquire Miromatrix Medical
Yahoo Finance
United Therapeutics
Miromatrix Medical
M&A
bioengineering
Flag link:
Amgen plans to lay off 350 former Horizon employees after $28B buyout
Amgen plans to lay off 350 former Horizon employees after $28B buyout
Fierce Pharma
Amgen
Horizon Therapeutics
layoffs
M&A
Flag link:
Roche pays $7.1B to Roivant for rights to Telavant’s IBD candidate
Roche pays $7.1B to Roivant for rights to Telavant’s IBD candidate
BioSpace
Roche
M&A
Televant
Roivant
RVT-3101
IBD
ulcerative colitis
Crohn’s disease
Flag link:
Jazz looks at strategic options, including possible sale or unit divestiture
Jazz looks at strategic options, including possible sale or unit divestiture
Fierce Pharma
Jazz Pharma
Xyrem
M&A
Flag link:
Pfizer wins unconditional EU antitrust okay for $43 billion Seagen buy
Pfizer wins unconditional EU antitrust okay for $43 billion Seagen buy
Reuters
Pfizer
Seagen
M&A
Europe
Flag link:
Lilly links up European ADC network, snagging Elahere rival in latest biotech buy
Lilly links up European ADC network, snagging Elahere rival in latest biotech buy
Fierce Biotech
Eli Lilly
M&A
antibody-drug conjugate
Elahere
Mablink
Flag link:
Takeda ponies up €130M to settle tax linked to distant AbbVie-Shire breakup fee
Takeda ponies up €130M to settle tax linked to distant AbbVie-Shire breakup fee
Fierce Pharma
Takeda
AbbVie
Shire
M&A
legal
Flag link:
Activist Icahn sues Illumina board over Grail acquisition
Activist Icahn sues Illumina board over Grail acquisition
Reuters
Illumina
Grail
M&A
Carl Icahn
Flag link:
Thermo Fisher Scientific to buy Olink in $3.1 billion deal
Thermo Fisher Scientific to buy Olink in $3.1 billion deal
Reuters
Thermo Fisher Scientific
M&A
Olink
Medtech
drug discovery
Flag link:
EU to Order Illumina to Sell Grail After Years of Regulatory Challenges
EU to Order Illumina to Sell Grail After Years of Regulatory Challenges
BioSpace
Illumina
Grail
diagnostics
M&A
Europe
Flag link:

Pages